Артериальная гипертония и цереброваскулярные нарушения

1. Гусев Е.И., Скворцова В.И. Ишемия головного мозга. М.: Медицина, 2001.
2. Wolf PA. Hypertension. In: Norris J, Hachinski VC, eds. Stroke Prevention. New York: Oxford University Press 2001; 93–105.
3. Wolf-Maier K, Cooper RS, Banegas JR et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363–9.
4. Скворцова В.И. Инсульт. Участие апоптоза в формировании инфаркта мозга. Приложение к Журн. неврол и психиатр им. С.С.Корсакова. 2001; 2: 12–9.
5. Чазова И.Е. Инсульт. Лечение артериальной гипертонии как профилактика ишемического инсульта. Приложение к Журн. неврол. и психиатр. им. С.С.Корсакова. 2001; 3: 3–7.
6. Gorelick PB. New horizons for stroke prevention: PROGRESS and HOPE. Lancet Neurol 2002; 1: 149–56.
7. Mac Mahon S, Peto R, Cutler J et al. Blood pressure, stroke and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. Lancet 1990; 335: 765–74.
8. Intengan HD, Schiffrin EL. Structure and mechanical properties of resistance arteries in hypertension: role of adhesion molecules and extracellular matrix determinants. Hypertension 2000; 36: 312–8.
9. Rodgers A, Mac Mahon S, Gamble G et al. Blood pressure and risk of stroke in patients with cerebrovascular disease. The United Kingdom Transient Ischaemic Attack Collaborative Group. BMJ 1996; 313: 147.
10. MacMahon S. Blood pressure and the risk of cardiovascular disease. N Engl J Med 2000; 342: 50–2.
11. Chillon JM, Baumbach GL. Autoregulation: arterial and intracranial pressure. In: Edvinsson L, Krause DN, eds. Cerebral Blood Flow and Metabolism. Philadelphia: Lippincott Williams & Wilkins; 2002; 395–412.
12. Верещагин Н.В., Калашникова Л.А., Гулевская Т.С., Миловидов Ю.К. Болезнь Бинсвангера и проблема сосудистой деменции: к столетию первого описания. Журн. неврол. и психиатр. им. С.С.Корсакова. 1995; 1: 98–103.
13. Levy BI, Safar ME. Remodelling of the vascular system in response to hypertension and drug therapy. Clin Exp Pharmacol Physiol Suppl 1992; 19: 33–7.
14. Chavakis T, Kanse SM, Yutzy B et al. Vitronectin concentrates proteolytic activity on the cell surface and extracellular matrix by trapping soluble urokinase receptor-urokinase complexes. Blood 1998; 91 (7): 2305–12.
15. Stepanova V, Jerke U, Sagach V et al. Urokinase-dependent human vascular smooth muscle cell adhesion requires selective vitronectin phosphorylation by ectoprotein kinase CK2. J Biol Chem 2002; 277 (12): 10265–72.
16. Tkachuk V, Stepanova V, Little PJ, Bobik A. Regulation and role of urokinase plasminogen activator in vascular remodelling. Clin Exp Pharmacol Physiol 1996; 23 (9): 759–65.
17. Bennett MR, Boyle JJ. Apoptosis of vascular smooth muscle cells in atherosclerosis. Atherosclerosis 1998; 138 (1): 3–9.
18. Kliche S, Waltenberger VEGF receptor signaling and endothelial function. J Life 2001; 52 (1–2): 61–6.
19. Loftus IM, Naylor AR, Bell PRF, Thompson MM. Matrix metalloproteinases and atherosclerotic plaque instability. Br J Surg 2002; 89 (6): 680–94.
20. Tsiamis AC, Morris PN, Marron MB, Brindle NP. Vascular endothelial growth factor modulates the Tie-2:Tie-1 receptor complex. Microvasc Res 2002; 63 (2): 149–58.
21. Gadeau AP, Campan M, Millet D et al. Osteopontin overexpression is associated with arterial smooth muscle cell proliferation in vitro. Arterioscler Thromb 1993; 13: 120–5.
22. Thyberga J, Blomgrena K, Royb J et al. Phenotypic modulation of smooth muscle cells after arterial injury Is associated with changes in the distribution of laminin and fibronectin. J Histochem Cytochem 1997; 45: 837–46.
23. De Vries HE, Moor AC, Blom-Roosemalen MC et al. Lymphocyte adhesion to brain capillary endothelial cells in vitro. J Neuroimmunol 1994; 52 (1): 1–8.
24. Chillon JM, Baumbach GL. Effects of an angiotensin-converting enzyme inhibitor and a beta-blocker on cerebral arteriolar dilatation in hypertensive rats. Hypertension 2001; 37: 1388–93.
25. Nag S, Robertson DM, Dinsdale HB. Cerebral cortical changes in acute experimental hypertension: An ultrastructural study. Lab Invest 1977; 36 (2): 150–61.
26. Nag S. Cerebral changes in chronic hypertension: combined permeability and immunohistochemical studies. Acta Neuropathol (Berl) 1984; 62 (3): 178–84.
27. Nag S. Cerebral endothelial plasma membrane alterations in acute hypertension. Acta Neuropathol (Berl) 1986; 70 (1): 38–43.
28. Nag S. Localisation of calcium-activated adenosine-triphosphatase (Ca2+-ATPase) in intracerebral arterioles in acute hypertension. Acta Neuropathol (Berl) 1988; 75 (6): 547–53.
29. Хвеледиани Д. Я. Ультраструктурные изменения артериол при гипертонии у человека. Кардиология 1977; 17 (2): 100–5.
30. Ferrario CM. Use of angiotensin II receptor blockers in animal models of atherosclerosis. Am J Hypertens 2002; 15: 9–13.
31. Dempsey RJ, Diana AL, Moore RW. Thickness of carotid artery atherosclerotic plaque and ischemic risk. Neurosurgery. 1990; 27 (3): 343–8.
32. Goldstein LB, Adams R, Becker K et al. Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke 2001; 32: 280.
33. O'Leary DH, Polak JF, Kronmal RA et al. Distribution and correlates of sonographically detected carotid artery disease in the Cardiovascular Health Study. The CHS Collaborative Research Group. Stroke 1992 Dec; 23 (12): 1752–60.
34. Cupini LM, Pasqualetti P, Diomedi M et al. Carotid artery intima-media thickness and lacunar versus nonlacunar infarcts. Stroke 2002; 33: 689.
35. Nawroth PP, Stem DM. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. Exp Med J 1986; 163: 740–5.
36. Tomita M, Fukuuchi Y, Terakawa S. Differential behavior of glial and neuronal cells exposed to hypotonic solution. Acta Neurochir 1994; 1 (60): 31–3.
37. Nagai Y, Kitagawa K, Matsumoto M. Implication of earlier carotid atherosclerosis for stroke and its subtypes. Prev Cardiol 2003; 6 (2): 99–103.
38. Vemmos KN, Tsivgoulis G, Spengos K et al. Common carotid artery intima-media thickness in patients with brain infarction and intracerebral haemorrhage. Cerebrovasc Dis 2004; 17 (4): 280–6.
39. Reckelhoff JF, Romero JC. Role of oxidative stress in angiotensin-induced hypertension. Am J Physiol Regul Integr Comp Physiol 2003; 284: 893–912.
40. Touyz RM, Schiffrin EL. Signal transduction mechanisms mediating the physiological and pathophysiological actions of angiotensin II in vascular smooth muscle cells. Pharmacol Rev 2000; 52: 639–72.
41. Saavedra JM, Nishimura Y. Angiotensin and cerebral blood flow. Cell Mol Neurobiol 1999; 19: 553–73.
42. Wood P. Differential regulation of IL-1 alpha and TNF alpha release from immortalized murine microglia (BV-2). Life Sci 1994; 55 (9): 661–8.
43. Cai H, Griendling KK, Harrison DG. The vascular NAD(P)H oxidases as therapeutic targets in cardiovascular diseases. Trends Pharmacol Sci 2003; 24: 471–8.
44. Kazama K, Anrather J, Wang G et al. Angiotensin II alters neurovascular coupling via production of reactive oxygen species. Cereb Blood Flow Metab 2003; 23 (1): 83–8.
45. Siren A-L, McCarron RM, Liu Y et al. Adhesion receptor expression and perivascular monocyte accumulation in carotid arteries and brains of hypertensive rats. In: Microcirculatory stasis in the brain (Tomita M, Mchedlishvili G, Rosenblum Wl., Heiss W-D, Fukuuchi Y eds.). Amsterdam, Excerpta Medica 1993; 169–75.
46. Banati RB, Gehrmann J, Kreutlberg GW. Early glial reactions in ischemic lesions, In: Cellular and Molecular Mechanisms of Ischemic Brain Damage, B.K. Siesjo and T. Wieloch, Advances in Neurology 1996; 71: 329–37.
47. Klahr S, Morrissey J. Angiotensin II and gene expression in the kidney. Am J Kidney Dis 1998; 31 (1): 171–6.
48. Blinzinger K, Kreutzberg G. Displacement of synaptic terminals from regenerating motoneurons by microglial cells. Z Zellforsch Mikrosk Anat 1968; 85: 145–57.
49. Nordan R, Potter M. Macrophage-derived factor required by plasmacytomas for survival and proliferation in vitro. Science 1986; 233 (4763): 566–9.
50. Schwanzel-Fukuda M, Abraham S, Crossin KL et al. Immunocytochemical demonstration of neural cell adhesion molecule (NCAM) along the migration route of luteinizing hormone-releasing hormone (LHRH) neurons in mice. J Comp Neurol 1992 Jul 1; 321 (1): 1–18.
51. Kojima K, Berger T, Lassmann H et al. Experimental autoimmune panencephalitis and uveoretinitis transferred to the Lewis rat by T lymphocytes specific for the S100 beta molecule, a calcium binding protein of astroglia. J Exp Med 1994; 180 (3): 817–29.
52. Штарк М.Б. Мозгоспецифические белки (антигены) и функция нейрона. М.: Медицина, 1989.
53. Скворцова В.И., Чазова И.Е., Стаховская Л.В. Вторичная профилактика инсульта. М.: ПАГРИ, 2002.
54. Хаджиева М.Х., Скворцова В.И., Шерстнев В.В. и др. Изучение нейротрофических факторов и аутоантител к ним у больных с хронической ишемией головного мозга. В кн.: Современные подходы к диагностике и лечению нервных и психических заболеваний. СПб., 2000.
55. Skvortsova VI, Gusev EI, Sherstnev VV et al. Neuroimmune mechanisms in pathogenesis of ischemic stroke. Cerebrovasc Dis 2000; 10 (2): 67–8.
56. Постнов Ю.В. К истокам первичной гипертонии: подход с позиции биоэнергетики. Кардиология. 1998; 12: 41–8.
57. Molkentin JD, Lu J-R, Anros CL et al. A calcineurin-dependent transcriptional pathway for cardiac hypertrophy. Cell 1988; 93: 215–28.
58. Sadoshima J., Izumo S. The cellular and molecular response of cardiac myocytes to mechanical stress. Ann Rev Physiol 1997; 59: 551–71.
59. Morgan JI, Curran T. Stimulus-transcription coupling in the nervous system: involvement of the inducible proto-oncogenes fos and jun. Annu Rev Neurol 1991; 14: 421–51.
60. Steng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron 1990; 4: 477–85.
61. Kim JS. Cytokines and adhesion molecules in stroke and related diseases. J Neural Sci 1996; 137: 69–78.
62. Iadecola C, Zhang P, Casey R et al. Inducible nitric oxide synthase gene expression in vascular cells after transient focal cerebral ischemia. Stroke 1996; 27: 1373–80.
63. Nogawa S, Zhang F, Ross ME, Iadecola C. Cyclo-oxygenase-2 gene expression in Neurons contributes to ischemic brain damage. J Neurosci 1997; 17: 2746–55.
64. Waters C. Mechanisms of neuronal cell death. An overview. Mol Chem Neuropathol 1996; 28 (1–3): 145–51.
65. Petito СК, Olarte J-P, Roberts B et al. Selective glial vulnerability following transient global ischemia in rat brain. J Neuropathol Exp Neurol 1998; 57: 231–8.
66. Gusev EI, Skvortsova VI. Brain Ischemia. New York - London - Berlin, Kluwer Academic Publishers, 2003.
67. Кушаковский М.С. Гипертоническая болезнь (эссенциальная гипертония): причины, механизмы, клиника, лечение. СПб.: СО ТИС, 1995.
68. Chowdhary S, Townend JN. Nitric oxide and hypertension: not just an endothelium derived relaxing factor. J Hum Hypertens 2001; 15 (4): 219–27.
69. Kataoka C, Egashira K, Inoue S et al. Important role of Rho-kinase in the pathogenesis of cardiovascular inflammation and remodeling induced by long-term blockade of nitric oxide synthesis in rats. Hypertension 2002; 39: 245–50.

В.И.Скворцова 

Российский государственный медицинский университет, Москва